Cargando…

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer

Poly(ADP-ribose) polymerase (PARP) inhibitors represent a promising strategy toward the treatment of triple-negative breast cancer (TNBC), which is often associated to genomic instability and/or BRCA mutations. However, clinical outcome is controversial and no benefits have been demonstrated in wild...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazzucchelli, S., Truffi, M., Baccarini, F., Beretta, M., Sorrentino, L., Bellini, M., Rizzuto, M. A., Ottria, R., Ravelli, A., Ciuffreda, P., Prosperi, D., Corsi, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548799/ https://www.ncbi.nlm.nih.gov/pubmed/28790402 http://dx.doi.org/10.1038/s41598-017-07617-7

Ejemplares similares

Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax
por: Sitia, Leopoldo, et al.
Publicado: (2021)

Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity
por: Mazzucchelli, Serena, et al.
Publicado: (2016)

Protein-Based Nanoparticles for the Imaging and Treatment of Solid Tumors: The Case of Ferritin Nanocages, a Narrative Review
por: Mainini, Francesco, et al.
Publicado: (2021)

Novel Bioengineering Strategies to Improve Bioavailability and In Vivo Circulation of H-Ferritin Nanocages by Surface Functionalization
por: Sevieri, Marta, et al.
Publicado: (2023)

Combined Method to Remove Endotoxins from Protein Nanocages for Drug Delivery Applications: The Case of Human Ferritin
por: Silva, Filippo, et al.
Publicado: (2021)

Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
por: Gagliardi, Stella, et al.
Publicado: (2022)

Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model
por: Andreata, F., et al.
Publicado: (2020)

Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
por: Ottria, Roberta, et al.
Publicado: (2019)

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
por: Avvakumova, S., et al.
Publicado: (2019)

Correction: Ottria, R., et al. Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS. Molecules 2019, 24, 989
por: Ottria, Roberta, et al.
Publicado: (2019)

Evaluation of TFR-1 Expression in Feline Mammary Cancer and In Vitro Antitumor Efficacy Study of Doxorubicin-Loaded H-Ferritin Nanocages
por: Rensi, Nicolò, et al.
Publicado: (2021)

Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity
por: Ferraro, Giarita, et al.
Publicado: (2021)

In Vitro Immunoreactivity Evaluation of H-Ferritin-Based Nanodrugs
por: Sitia, Leopoldo, et al.
Publicado: (2023)

Ferritin Nanocages for Protein Delivery to Tumor Cells
por: Palombarini, Federica, et al.
Publicado: (2020)

Evaluation of Auranofin Loading within Ferritin Nanocages
por: Lucignano, Rosanna, et al.
Publicado: (2022)

Bacterioferritin nanocage structures uncover the biomineralization process in ferritins
por: Jobichen, Chacko, et al.
Publicado: (2023)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines
por: Bonizzi, Arianna, et al.
Publicado: (2019)

Ferritin in cancer therapy: A pleiotropic tumoraffin nanocage‐based transport
por: Deng, Guodong, et al.
Publicado: (2023)

Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells
por: Truffi, Marta, et al.
Publicado: (2018)

Ferritin Nanocage: A Versatile Nanocarrier Utilized in the Field of Food, Nutrition, and Medicine
por: Zhang, Chenxi, et al.
Publicado: (2020)

Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer
por: Mazzucchelli, S., et al.
Publicado: (2019)

Design and site-directed compartmentalization of gold nanoclusters within the intrasubunit interfaces of ferritin nanocage
por: Zang, Jiachen, et al.
Publicado: (2019)

Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development
por: Reutovich, Aliaksandra A., et al.
Publicado: (2023)

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy
por: Truffi, Marta, et al.
Publicado: (2019)

GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy
por: Jiang, Bing, et al.
Publicado: (2019)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
por: Varanda, Ana Beatriz, et al.
Publicado: (2020)

Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy
por: Wang, Zhuoran, et al.
Publicado: (2022)

A new and efficient procedure to load bioactive molecules within the human heavy-chain ferritin nanocage
por: Lucignano, Rosanna, et al.
Publicado: (2023)

Tumor Accumulation and Off-Target Biodistribution of an Indocyanine-Green Fluorescent Nanotracer: An Ex Vivo Study on an Orthotopic Murine Model of Breast Cancer
por: Sevieri, Marta, et al.
Publicado: (2021)

Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
por: Yoo, Jae Do, et al.
Publicado: (2020)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

Development of Tumor-Targeted Indocyanine Green-Loaded Ferritin Nanoparticles for Intraoperative Detection of Cancers
por: Sitia, Leopoldo, et al.
Publicado: (2020)

Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages
por: Kalathiya, Umesh, et al.
Publicado: (2021)

Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
por: Exman, Pedro, et al.
Publicado: (2019)

Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease
por: Truffi, Marta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_duvvg0rdm0lt7cd9c9i5c1q88l